Holen Sie sich die Stockscreener-App
95.65
7.03%
-7.23
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences names new Chief Medical Officer By Investing.com - Investing.com South Africa
Neurocrine Biosciences appoints new chief medical officer - The Pharma Letter
UBS cuts Neurocrine Bio. stock target to $137, keeps Buy rating - Investing.com UK
Neurocrine Biosciences names new Chief Medical Officer - Investing.com India
Neurocrine Biosciences Appoints Sanjay Keswani as Chief Medical Officer - Contract Pharma
Neurocrine Biosciences Appoints Dr. Sanjay Keswani As Chief Medical Officer - MarketScreener
Neurocrine Biosciences (NBIX) Appoints Dr. Sanjay Keswani as Chief Medical Officer - StreetInsider
Pharma Veteran Behind Major Drug Approvals to Lead Neurocrine's Clinical Pipeline - Stock Titan
Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $135 From $138, Maintains Hold Rating - MarketScreener
Neurocrine Biosci stock hits 52-week low at $105.17 By Investing.com - Investing.com South Africa
UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating - MarketScreener
Neurocrine Biosci stock hits 52-week low at $105.17 - Investing.com
Cerebral Palsy Market Growth Projections 2024-2034: DelveInsight Analysis | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - The Globe and Mail
Mitsubishi UFJ Trust & Banking Corp Sells 4,578 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences executive sells shares worth $266,024 - MSN
New Data: INGREZZA Outperforms Competitors with Perfect Therapeutic Dose Rate - Stock Titan
Supporting a Loved One Living with a Mental Health Condition and Tardive Dyskinesia - Main Street Media of Tennessee
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential - The Globe and Mail
Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings) - Benzinga
Ashland, Connectone Bancorp, Neurocrine Biosciences - TradingView
Tardive Dyskinesia Treatment Market Expands with New Drug - openPR
Neurocrine Biosciences debuts new data for effectiveness of Ingrezza - Yahoo Finance
Neurocrine touts further positive trial results for Ingrezza - The Pharma Letter
Neurocrine Biosciences (NBIX) Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA Capsules - StreetInsider.com
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules - PR Newswire
Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR
Neurocrine at Stifel 2025 CNS Forum: Strategic Insights and Challenges - Investing.com
Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Is Neurocrine Biosciences, Inc. (NBIX) a Best Biotech Stock According to Billionaires? - Insider Monkey
Neurocrine Biosciences Presents New Data From KINECT-HD Study Of Ingrezza - Nasdaq
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules - The Victoria Advocate
Breakthrough: INGREZZA Phase 3 Data Reveals Powerful Chorea Control Across All Body Regions - Stock Titan
Neurocrine Biosciences chief legal officer sells $254,991 in stock - MSN
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews.com - Defense World
Schizophrenia Treatment Market Size Report 2034 | Novartis - openPR
US Bancorp DE Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
RBC Capital cuts Neurocrine Bio. stock target to $139 from $148 - Investing.com India
Trend Tracker for (NBIX) - Stock Traders Daily
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum - PR Newswire
RBC Cuts Price Target on Neurocrine Biosciences to $139 From $148, Keeps Sector Perform Rating - Marketscreener.com
Smartleaf Asset Management LLC Purchases 146 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Neurocrine Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Morgan Stanley Reiterates Overweight Rating for Neurocrine Biosciences (NASDAQ:NBIX) - Defense World
Positive Growth Outlook for Neurocrine Biosciences Driven by Ingrezza and Crenessity Sales Projections - TipRanks
Tardive Dyskinesia Treatment Market Size, Share & Future - openPR
Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions - Simply Wall St
Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults - Yahoo Finance
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating NBI-1140675 - Marketscreener.com
Neurocrine begins phase 1 study of new neurological drug By Investing.com - Investing.com South Africa
Neurocrine begins phase 1 study of new neurological drug - Investing.com India
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults - PR Newswire
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock Retreats 25% But Earnings Haven't Escaped The Attention Of Investors - Simply Wall St
Neurological Disorder Drugs Market Detailed In New Research - openPR
Neurocrine Biosci stock hits 52-week low at $110.92 - Investing.com
6.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):